NeoglycyrolCAS# 23013-84-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 23013-84-5 | SDF | Download SDF |
| PubChem ID | 5320083 | Appearance | Powder |
| Formula | C21H18O6 | M.Wt | 366.4 |
| Type of Compound | Coumarins | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one | ||
| SMILES | CC(=CCC1=C(C=C2C(=C1OC)C3=C(C4=C(O3)C=C(C=C4)O)C(=O)O2)O)C | ||
| Standard InChIKey | LWESBHWAOZORCQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H18O6/c1-10(2)4-6-12-14(23)9-16-18(19(12)25-3)20-17(21(24)27-16)13-7-5-11(22)8-15(13)26-20/h4-5,7-9,22-23H,6H2,1-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Neoglycyrol shows some cardioprotective effects . |
| In vitro | Screening of active compounds with myocardial protective effects from Tongmai Yangxin pill[Pubmed: 26038132]Zhejiang Da Xue Xue Bao Yi Xue Ban. 2015 Mar;44(2):145-53.Based on cell model and HPLC-MS technology, to screen myocardial protection active compounds from traditional patent medicine Tongmai Yangxin pill (TMYXP).
|
Neoglycyrol Dilution Calculator
Neoglycyrol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7293 mL | 13.6463 mL | 27.2926 mL | 54.5852 mL | 68.2314 mL |
| 5 mM | 0.5459 mL | 2.7293 mL | 5.4585 mL | 10.917 mL | 13.6463 mL |
| 10 mM | 0.2729 mL | 1.3646 mL | 2.7293 mL | 5.4585 mL | 6.8231 mL |
| 50 mM | 0.0546 mL | 0.2729 mL | 0.5459 mL | 1.0917 mL | 1.3646 mL |
| 100 mM | 0.0273 mL | 0.1365 mL | 0.2729 mL | 0.5459 mL | 0.6823 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- MPTP hydrochloride
Catalog No.:BCC1778
CAS No.:23007-85-4
- Atazanavir sulfate (BMS-232632-05)
Catalog No.:BCC2114
CAS No.:229975-97-7
- AGN 194310
Catalog No.:BCC5416
CAS No.:229961-45-9
- GW9662
Catalog No.:BCC2260
CAS No.:22978-25-2
- Abn-CBD
Catalog No.:BCC7011
CAS No.:22972-55-0
- Desmethoxycentaureidin
Catalog No.:BCN5077
CAS No.:22934-99-2
- Neferine
Catalog No.:BCN6338
CAS No.:2292-16-2
- Ginkgolic acid C15:1
Catalog No.:BCN2307
CAS No.:22910-60-7
- R 892
Catalog No.:BCC5992
CAS No.:229030-05-1
- TAK-779
Catalog No.:BCC4137
CAS No.:229005-80-5
- 4-Amino-3,5-dichloropyridine
Catalog No.:BCC8679
CAS No.:22889-78-7
- Silymarin
Catalog No.:BCN6299
CAS No.:22888-70-6
- Physalin A
Catalog No.:BCN7920
CAS No.:23027-91-0
- Apelin-36 (rat, mouse)
Catalog No.:BCC5911
CAS No.:230299-95-3
- Terbutaline Sulfate
Catalog No.:BCC4320
CAS No.:23031-32-5
- Z-β-Ala-OH
Catalog No.:BCC3058
CAS No.:2304-94-1
- Z-Asn-OH
Catalog No.:BCC2794
CAS No.:2304-96-3
- Z-Arg(NO2)-OH
Catalog No.:BCC3063
CAS No.:2304-98-5
- Ajugasterone C
Catalog No.:BCN2757
CAS No.:23044-80-6
- Lofepramine
Catalog No.:BCC7402
CAS No.:23047-25-8
- Dihydroconiferyl alcohol
Catalog No.:BCN7047
CAS No.:2305-13-7
- L-AP4
Catalog No.:BCC6550
CAS No.:23052-81-5
- (-)-Sophoranone
Catalog No.:BCN7162
CAS No.:23057-55-8
- Sinensetin
Catalog No.:BCN6356
CAS No.:2306-27-6
[Screening of active compounds with myocardial protective effects from Tongmai Yangxin pill].[Pubmed:26038132]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2015 Mar;44(2):145-53.
OBJECTIVE: Based on cell model and HPLC-MS technology, to screen myocardial protection active compounds from traditional patent medicine Tongmai Yangxin pill (TMYXP). METHODS: Fractions of TMYXP were prepared by high performance liquid preparation technology. The cardioprotective effects of prepared fractions were tested on H2O2 oxidation-damaged H9c2 myocardiocytes. The active components were analyzed by high performance liquid chromatography (HPLC) coupled with high resolution mass spectrometry. The possible active compounds were putatively identified by comparison of their MS ions and molecular weight with literatures. RESULTS: Ten TMYXP components presented significant myocardial protective activities, 5 of which were investigated and presented good dose-effect relationships. Their median effective concentrations (EC50) were respectively 11.66, 17.44, 13.10, 7.332, 15.15 mug/mL. Totally, 11 potential active compounds were analyzed and identified, including Glycyrrhizic acid, Glycycoumarin, Licoisoflavone, Ophiopogonin D', Licoricon, Gancaonin L, Neoglycyrol, Emodin, Angeloylgomisin H, Angeloylgomisin Q and Glyasperin A. CONCLUSION: The myocardial protection active compounds of TMYXP were screened successfully.
